The incidence of atherosclerosis is increasing rapidly all over the world. Inflammatory processes
have outstanding role in coronary artery disease (CAD) etiology and other atherosclerosis
manifestations. Recently attentions have been increased about gut microbiota in many fields of
medicine especially in inflammatory diseases like atherosclerosis. Ineffectiveness in gut barrier
functions and subsequent metabolic endotoxemia (caused by rise in plasma lipopolysaccharide
levels) is associated with low-grade chronic inflammation i.e. a recognized feature of
atherosclerosis. Furthermore, the role of trimethylamine-N-oxide (TMAO), a gut bacterial
metabolite has been suggested in atherosclerosis development. On the other hand, the effectiveness
of gut microbiota modulation that results in TMAO reduction has been investigated. Moreover,
considerable evidence supports a role for the endocannabinoid system (ECS) in atherosclerosis
pathology which affects gut microbiota, but their effects on atherosclerosis are controversial.
Therefore, we presented some evidence about the relationship between gut microbiota and ECS
in atherosclerosis. We also presented evidences that gut microbiota modulation by pre/probiotics
can have significant influence on the ECS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.